Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Grape derived polyphenols attenuate tau neuropathology in a mouse model of Alzheimer's disease.

Wang J, Santa-Maria I, Ho L, Ksiezak-Reding H, Ono K, Teplow DB, Pasinetti GM.

J Alzheimers Dis. 2010;22(2):653-61. doi: 10.3233/JAD-2010-101074.

PMID:
20858961
2.

Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies.

Pasinetti GM, Ksiezak-Reding H, Santa-Maria I, Wang J, Ho L.

J Neurochem. 2010 Sep;114(6):1557-68. doi: 10.1111/j.1471-4159.2010.06875.x. Review.

4.

[Neuropathology of tauopathy].

Yoshida M.

Brain Nerve. 2013 Dec;65(12):1445-58. Review. Japanese.

PMID:
24323931
6.

Invited review: Neuropathology of tauopathies: principles and practice.

Kovacs GG.

Neuropathol Appl Neurobiol. 2015 Feb;41(1):3-23. doi: 10.1111/nan.12208. Review.

PMID:
25495175
7.

Mutations causing neurodegenerative tauopathies.

Goedert M, Jakes R.

Biochim Biophys Acta. 2005 Jan 3;1739(2-3):240-50. Review.

8.

GSPE interferes with tau aggregation in vivo: implication for treating tauopathy.

Santa-Maria I, Diaz-Ruiz C, Ksiezak-Reding H, Chen A, Ho L, Wang J, Pasinetti GM.

Neurobiol Aging. 2012 Sep;33(9):2072-81. doi: 10.1016/j.neurobiolaging.2011.09.027.

9.

The neuropathological spectrum of neurodegenerative tauopathies.

Tolnay M, Probst A.

IUBMB Life. 2003 Jun;55(6):299-305. Review.

10.

REVIEW: tau protein pathology in Alzheimer's disease and related disorders.

Tolnay M, Probst A.

Neuropathol Appl Neurobiol. 1999 Jun;25(3):171-87. Review.

PMID:
10417659
11.

Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.

Navarrete LP, Pérez P, Morales I, Maccioni RB.

Curr Alzheimer Res. 2011 Sep;8(6):678-85. Review.

PMID:
21605038
12.

New insights into genetic and molecular mechanisms of brain degeneration in tauopathies.

Forman MS, Lee VM, Trojanowski JQ.

J Chem Neuroanat. 2000 Dec;20(3-4):225-44. Review.

PMID:
11207421
13.

Tau-based treatment strategies in neurodegenerative diseases.

Schneider A, Mandelkow E.

Neurotherapeutics. 2008 Jul;5(3):443-57. doi: 10.1016/j.nurt.2008.05.006. Review.

14.

Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes.

Mailliot C, Sergeant N, Bussière T, Caillet-Boudin ML, Delacourte A, Buée L.

FEBS Lett. 1998 Aug 21;433(3):201-4.

15.

Neurodegenerative tauopathies.

Lee VM, Goedert M, Trojanowski JQ.

Annu Rev Neurosci. 2001;24:1121-59. Review.

PMID:
11520930
16.

Ultrastructural alterations of Alzheimer's disease paired helical filaments by grape seed-derived polyphenols.

Ksiezak-Reding H, Ho L, Santa-Maria I, Diaz-Ruiz C, Wang J, Pasinetti GM.

Neurobiol Aging. 2012 Jul;33(7):1427-39. doi: 10.1016/j.neurobiolaging.2010.11.006.

PMID:
21196065
17.

Astrocytes expressing hyperphosphorylated tau protein without glial fibrillary tangles in argyrophilic grain disease.

Botez G, Probst A, Ipsen S, Tolnay M.

Acta Neuropathol. 1999 Sep;98(3):251-6.

PMID:
10483782
18.

Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies.

Iqbal K, Grundke-Iqbal I.

Curr Drug Targets. 2004 Aug;5(6):495-502. Review.

PMID:
15270196
19.

Nitration of tau protein is linked to neurodegeneration in tauopathies.

Horiguchi T, Uryu K, Giasson BI, Ischiropoulos H, LightFoot R, Bellmann C, Richter-Landsberg C, Lee VM, Trojanowski JQ.

Am J Pathol. 2003 Sep;163(3):1021-31. Erratum in: Am J Pathol. 2003 Dec;163(6):2645.

20.

Supplemental Content

Support Center